INDIVIDUAL ARTICLE: Vehicles Matter: Calcipotriene and Betamethasone Dipropionate Foam as a Topical Psoriasis Therapy.
J Drugs Dermatol
; 22(9): s5-s14, 2023 Sep 01.
Article
en En
| MEDLINE
| ID: mdl-37874778
ABSTRACT
Topical medications are commonly used to manage mild-to-moderate psoriasis and serve as adjunct therapies used in combination with phototherapy and systemic treatments. Fixed-dose calcipotriene (Cal) 0.005%/betamethasone dipropionate (BD) 0.064% aerosol foam is a safe, efficacious topical therapy approved for the treatment of psoriasis vulgaris in the United States and European Union. Several investigator-initiated studies (IISs) have been conducted to provide real-world evidence related to the safety, effectiveness, and therapeutic indications of Cal/BD foam and are relevant to clinicians' every-day practice. This paper summarizes the findings of the IISs around the globe published to date and presents the real-world data related to the effectiveness and clinical considerations of Cal/BD foam as a treatment for psoriasis.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Fármacos Dermatológicos
Idioma:
En
Revista:
J Drugs Dermatol
Año:
2023
Tipo del documento:
Article